US Food and Drug Administration Extends Safety Review of Mifepristone into Next Year

The US Food and Drug Administration (FDA) has announced that its ongoing safety review of mifepristone, the nation's primary abortion pill, will extend into next year.

In a court-ordered update filed on Wednesday, the FDA provided details about the reevaluation process initiated by Health Secretary Robert F. Kennedy Jr. The agency has been reviewing the safety and effectiveness of mifepristone since last year, following intense pressure from anti-abortion groups and their allies in Congress.

Mifepristone was initially approved by the FDA in 2000 and has undergone several regulatory changes since then. Despite repeated affirmations of its safety, some restrictions on the drug's use have been relaxed, including the requirement for in-person dispensing.

Abortion opponents have long pushed for tighter controls on mifepristone, citing concerns about its safety record. Since President Donald Trump took office, they have gained momentum, seeking to restrict access to the pill through legislative and administrative means.

The FDA's latest filing outlines a timeline for completing a comprehensive safety study of mifepristone by mid-December this year, with a report on the findings due no later than March 2027.

The FDA's ongoing review of mifepristone has sparked criticism from anti-abortion groups. Gavin Oxley, a spokesperson for Americans United for Life, accused the administration of lacking leadership in addressing the safety concerns surrounding the medication.

Mifepristone is part of a two-drug regimen that accounts for the majority of abortions performed in the US, typically combined with misoprostol to terminate pregnancies. This combination has been widely used since its approval by the FDA in 2000.

A federal judge had ordered the FDA to provide an update on its review, as part of a case brought by Louisiana against mail-delivery of mifepristone, which allegedly undermines the state's abortion ban. The lawsuit is one of several ongoing cases related to the medication.

The 5th US Circuit Court of Appeals has been reviewing the merits of Louisiana's case, including whether the state has the legal authority to challenge the FDA's oversight of mifepristone. A ruling from this court would not immediately change the situation, as the Supreme Court has blocked changes to the drug pending further review.

The FDA is using a statistical data mining method to identify potential unknown safety concerns associated with mifepristone. This involves analyzing electronic databases that collect reports of medical injuries and side effects from major health networks and insurers.

The FDA has announced that its ongoing safety review of mifepristone will continue into next year, with a focus on analyzing electronic databases that collect reports of medical injuries and side effects from major health networks and insurers.

As part of this process, the agency is considering petitions proposing changes to how mifepristone is prescribed and distributed. These petitions have been submitted by various groups, although details about their specific proposals are not specified in the announcement.

The FDA's safety review comes as abortion opponents continue to challenge the 2021 decision allowing doctors to prescribe mifepristone online and send it through the mail during COVID-19, a move that was made permanent under President Joe Biden in 2023.